Precigen, Inc. (PGEN) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 30, 2020 (filed February 4, 2020), covers material events for Precigen, Inc. (formerly Intrexon Corporation). The report details the completion of a major asset divestiture, a corporate name change, and a related equity financing transaction.
Key Financial Metrics and Transaction Details
- Asset Sale Proceeds: The company sold bioengineering assets to TS Biotechnology Holdings, LLC for an aggregate purchase price of approximately $53 million, plus certain contingent payment rights.
- Equity Financing: TS Biotechnology purchased 5,972,696 shares of the company's common stock for $35 million under a subscription agreement.
- Assets Divested: The sale included the domain name dna.com and equity interests in six subsidiaries: Blue Marble AgBio LLC, ILH Holdings, Inc., Intrexon Produce Holdings, Inc., Intrexon UK Holdings Inc., Oragenics, Inc., and SH Parent, Inc.
- Financial Statements: The filing does not provide current revenue, profit, cash flow, or debt metrics. Pro forma financial information is scheduled to be filed separately within four business days of the transaction completion.
Material Changes and Corporate Actions
- Name Change: The company changed its name from Intrexon Corporation to Precigen, Inc., effective February 1, 2020.
- Trading Symbol: The trading symbol for common stock changed from "XON" to "PGEN" effective February 3, 2020.
- Charter Amendments: The company amended its Articles of Incorporation to delete provisions regarding Series A Redeemable Preferred Stock, of which no shares were ever issued.
- Related Party Transaction: The asset buyer, TS Biotechnology, is managed by Third Security, LLC. Randal J. Kirk, the company's Executive Chairman, owns 100% of Third Security and beneficially owns approximately 48.2% of the company's voting stock. Third Security is deemed to beneficially own approximately 34.6% of the common stock.
Outlook, Risks, and Contingencies
The transaction was approved by an independent special committee of the Board of Directors following a strategic review. The filing notes that pro forma financial information will be provided in a subsequent Form 8-K/A. No specific forward-looking guidance or risk factors beyond the standard disclosure of the related-party nature of the transaction are detailed in this specific filing text.
Key Facts for Investor Verification
- Verify the total cash consideration received ($53 million asset sale + $35 million equity purchase) against the company's liquidity position in the upcoming pro forma filing.
- Confirm the valuation of the contingent payment rights associated with the asset sale.
- Review the subsequent Form 8-K/A for pro forma financial statements to understand the impact of the divestiture on the company's balance sheet and operations.
- Assess the ongoing relationship and potential conflicts of interest given Randal J. Kirk's dual role as Executive Chairman and CEO of the buyer's manager.